An event focusing on the way in which CBD is being regulated and legislated on was held in London last week. The discussions were led by Mark Tucker, the CEO of TTS Pharma.
The key note speaker started off by observing that while cannabidiol (CBD) isn’t a controlled substance, all the processors or manufacturers extracting this cannabinoid needed to have a Controlled Drugs license.
This is because regulators were interested in ensuring that the extraction process gets rid of or reduces to legally accepted limits, the amounts of THC and CBN. THC and CBN are controlled substances because they can cause users to be high.
Tucker also responded to questions regarding how to grow hemp and keep its THC content within the 0.2 percent legal limit set in the UK. Tucker said that routine testing is needed to know just when to harvest hemp before its THC content rises too high. He suggested that if the THC concentration exceeds 1 percent while the plants are still in the field, then one must leave them there longer so that the THC degrades and comes back down to the acceptable level.
He also expressed concerns about the way in which some CBD products on the European market were labeled. For example, he says that he has seen a number of products being marketed as “THC-free” and yet those very products contain CBN, which is a psychoactive form of degraded THC.
Many speakers also called for more comprehensive CBD product labeling requirements in order to reflect other concerns arising from the very nature of the hemp plant. Tucker had earlier explained that hemp is very good at absorbing toxins from the soil in which it is grown. Product labels should therefore indicate the level of mycotoxins and carcinogens in a given product.
The experts during the event cautioned that a consumer may not suffer from a single exposure to those toxins, but health risks are more likely to arise over the years as people accumulate these toxins in their bodies.
Tucker also talked about the matter of the health benefits attributed to using CBD products. He noted that there is a limit as to what benefits can be attributed to a supplement, and there are acceptable standards of what a medicine can do.
The success of the CBD industry may therefore depend on how regulators manage to draw a line between the use of CBD as a supplement or as a drug.
It would be enlightening to hear what suggestions CBD industry players like Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) and Willow Biosciences Inc. (CSE: WLLW) would have to say regarding how to fix some of the challenges highlighted during the event in London.
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor